Design Therapeutics, Inc. (DSGN) intrinsic value & 10-year financials
Design Therapeutics, Inc. (DSGN) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 7 fiscal years revenue reached to $0, with an average return on invested capital of -8.4%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $10.31
- Market cap
- $591.1M
- Revenue (FY2025)
- $0
- ROIC (10-yr avg)
- -8.4%
- Free cash flow (FY2025)
- -$54.6M
DSGN 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $0 | -$69.8M | -$1.22 | -$54.6M | — | -38.1% |
| FY2024 | $0 | -$49.6M | -$0.88 | -$43.4M | — | -26.0% |
| FY2023 | — | -$66.9M | -$1.19 | -$58.8M | — | -23.8% |
| FY2022 | — | -$63.3M | -$1.14 | -$52.2M | — | -32.4% |
| FY2021 | — | -$35.5M | -$0.77 | -$30.9M | — | -41.0% |
| FY2020 | $226.0K | -$8.3M | — | -$8.7M | -3685.8% | 110.7% |
| FY2019 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Design Therapeutics, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Design Therapeutics, Inc. has historically struggled to out-earn its cost of capital, averaging just -32.2% ROIC.
Design Therapeutics, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Design Therapeutics, Inc. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.